MYCOF OTC
Noveris Health Sciences Inc.
1W: +0.0%
1M: +0.0%
3M: -63.5%
YTD: +234.9%
1Y: +12066.7%
3Y: +350.6%
5Y: +96.8%
$0.73
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+100.0% ▲
Operating Income
-$2M
+73.5% ▲
Net Income
-$3M
+85.0% ▲
EPS (Diluted)
$-0.05
+92.2% ▲
EBITDA
-$2M
+73.6% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $3K | $7K | $0 | $0 | $0 |
| YoY Growth | -97.9% | +186.3% | -100.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $129K | $10K | $0 |
| Gross Profit | $3K | $7K | -$129K | -$10K | $0 |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| R&D Expenses | $1M | $4M | $4M | $1M | $0 |
| SG&A Expenses | $10M | $15M | $10M | $8M | $2M |
| Operating Expenses | $11M | $22M | $16M | $9M | $2M |
| Operating Income | -$11M | -$22M | -$16M | -$9M | -$2M |
| Operating Margin | -428262.5% | -294931.0% | — | — | — |
| Interest Expense | $183K | $205K | $912K | $1M | $1M |
| Income Before Tax | -$27M | -$24M | -$16M | -$21M | -$3M |
| Tax Expense | $608K | $0 | -$5M | $0 | $0 |
| Net Income | -$27M | -$29M | -$12M | -$21M | -$3M |
| Net Margin | -1029764.8% | -385658.6% | — | — | — |
| EPS (Diluted) | $-11.82 | $-6.17 | $-1.37 | $-0.68 | $-0.05 |
| EBITDA | -$11M | -$23M | -$16M | -$9M | -$2M |
| Shares Outstanding | 2M | 5M | 9M | 31M | 60M |